Secura Bio Acquires WW Commercialization Rights to Novartis’ Farydak for R/R Multiple Myeloma

Shots:

• Secure Bio to get WW commercialization rights for Farydak (panobinostat) from Novartis to treat patients with r/r multiple myeloma with no prior treatment
• The focus of the acquisition is to expand Secura Bio’s oncology portfolio and develop new product combinations for Farydak
• Farydak (panobinostat, PO) is a histone deacetylase (HDAC) inhibitor & decreases the growth of myeloma cells. On February 23 & August 28, 2015, it has received the FDA’s accelerated approval & EU’s approval for the same indication and is marketed in 53 countries

Click here to read full press release/ article | Ref: PRNewswire | Image: Secura Bio